These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 25483677)

  • 21. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ICOSL-augmented adenoviral-based vaccination induces a bipolar Th17/Th1 T cell response against unglycosylated MUC1 antigen.
    Carrell RK; Stanton RA; Ethier SP; LaRue AC; Soloff AC
    Vaccine; 2018 Oct; 36(42):6262-6269. PubMed ID: 30219366
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What future opportunities may immuno-oncology provide for improving the treatment of patients with lung cancer?
    Reck M
    Ann Oncol; 2012 Sep; 23 Suppl 8():viii28-34. PubMed ID: 22918925
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early recovery of aggressive cytotoxic cells and improved immune resurgence with post-transplant immunotherapy for multiple myeloma.
    Meehan KR; Wu J; Bengtson E; Hill J; Ely P; Szczepiorkowski Z; Kendall M; Ernstoff MS
    Bone Marrow Transplant; 2007 Jun; 39(11):695-703. PubMed ID: 17417660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21.
    Dou J; Wu Y; Wang J; Zhao F; Chu L; Liu C; Wen P; Hu W; Hu K; He XF; Gu N
    Cancer Gene Ther; 2010 Oct; 17(10):675-83. PubMed ID: 20539320
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer.
    Butts C; Murray RN; Smith CJ; Ellis PM; Jasas K; Maksymiuk A; Goss G; Ely G; Beier F; Soulières D
    Clin Lung Cancer; 2010 Nov; 11(6):391-5. PubMed ID: 21071331
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.
    Kuball J; de Boer K; Wagner E; Wattad M; Antunes E; Weeratna RD; Vicari AP; Lotz C; van Dorp S; Hol S; Greenberg PD; Heit W; Davis HL; Theobald M
    Cancer Immunol Immunother; 2011 Feb; 60(2):161-71. PubMed ID: 20963411
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer.
    Ramlau R; Quoix E; Rolski J; Pless M; Lena H; Lévy E; Krzakowski M; Hess D; Tartour E; Chenard MP; Limacher JM; Bizouarne N; Acres B; Halluard C; Velu T
    J Thorac Oncol; 2008 Jul; 3(7):735-44. PubMed ID: 18594319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
    Karanikas V; Thynne G; Mitchell P; Ong CS; Gunawardana D; Blum R; Pearson J; Lodding J; Pietersz G; Broadbent R; Tait B; McKenzie IF
    J Immunother; 2001; 24(2):172-83. PubMed ID: 11265775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma.
    Szmania S; Gnjatic S; Tricot G; Stone K; Zhan F; Moreno A; Thuro B; Melenhorst J; Barrett J; Shaughnessy J; Old LJ; Barlogie B; Brichard VG; van Rhee F
    J Immunother; 2007; 30(8):847-54. PubMed ID: 18049337
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
    Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Drug-mediated and cellular immunotherapy in multiple myeloma.
    Ritchie DS; Quach H; Fielding K; Neeson P
    Immunotherapy; 2010 Mar; 2(2):243-55. PubMed ID: 20635931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor necrosis factor gene-engineered J558 tumor cell-released exosomes stimulate tumor antigen P1A-specific CD8+ CTL responses and antitumor immunity.
    Xie Y; Bai O; Zhang H; Li W; Xiang J
    Cancer Biother Radiopharm; 2010 Feb; 25(1):21-8. PubMed ID: 20187793
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens.
    Apostolopoulos V; Xing PX; McKenzie IF
    Cancer Res; 1994 Oct; 54(19):5186-93. PubMed ID: 7923138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin.
    Noto H; Takahashi T; Makiguchi Y; Hayashi T; Hinoda Y; Imai K
    Int Immunol; 1997 May; 9(5):791-8. PubMed ID: 9184925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Antigen-specific Immunotherapy in the Treatment of Patients with Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis.
    Yan BD; Cong XF; Zhao SS; Ren M; Liu ZL; Li Z; Chen C; Yang L
    Curr Cancer Drug Targets; 2019; 19(3):199-209. PubMed ID: 29714142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma.
    Rosenblatt J; Vasir B; Uhl L; Blotta S; Macnamara C; Somaiya P; Wu Z; Joyce R; Levine JD; Dombagoda D; Yuan YE; Francoeur K; Fitzgerald D; Richardson P; Weller E; Anderson K; Kufe D; Munshi N; Avigan D
    Blood; 2011 Jan; 117(2):393-402. PubMed ID: 21030562
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival.
    Dobrzanski MJ; Rewers-Felkins KA; Quinlin IS; Samad KA; Phillips CA; Robinson W; Dobrzanski DJ; Wright SE
    Clin Immunol; 2009 Dec; 133(3):333-52. PubMed ID: 19762283
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A novel multi-epitope vaccine from MMSA-1 and DKK1 for multiple myeloma immunotherapy.
    Lu C; Meng S; Jin Y; Zhang W; Li Z; Wang F; Wang-Johanning F; Wei Y; Liu H; Tu H; Su D; He A; Cao X; Zhou F
    Br J Haematol; 2017 Aug; 178(3):413-426. PubMed ID: 28508448
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.
    Scheid E; Major P; Bergeron A; Finn OJ; Salter RD; Eady R; Yassine-Diab B; Favre D; Peretz Y; Landry C; Hotte S; Mukherjee SD; Dekaban GA; Fink C; Foster PJ; Gaudet J; Gariepy J; Sekaly RP; Lacombe L; Fradet Y; Foley R
    Cancer Immunol Res; 2016 Oct; 4(10):881-892. PubMed ID: 27604597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.